ClinicalTrials.gg
CompletedNCT04101383Updated Sep 24, 2019

A Study to Compare Pharmacokinetics and Pharmacodynamics of RinGlar® to Lantus® in Type 1 Diabetes Mellitus Patients

An interventional study of RinGlar® and Lantus® in Clamp Study, sponsored by Geropharm. Completed at 2 sites in Russian Federation. Open to male participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-09-24.

Sponsored by Geropharm · Not applicable, Interventional, and Basic science

From the registry’s dates

  • Registered 1 year 11 months after the study started (first participant enrolled Oct 2017, registered Sep 2019).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
42
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

Pharmacokinetics and pharmacodynamics study of 2 formulation of insulin glargine (RinGlar® GEROPHARM vers. Lantus® Sanofi-Aventis)

Read the detailed description

A randomized double blinded two-way crossover single-dose pharmacokinetics and pharmacodynamics study of RinGlar® (LLC "GEROPHARM", Russia) versus Lantus® (Sanofi-Aventis) in Type 1 Diabetes Mellitus Patients using the euglycemic clamp technique

02

Conditions studied

  • Clamp Study

Keywords

  • Pharmacokinetics
  • Pharmacodynamics
  • Insulin glargine
03

In context

Lead sponsor

Geropharm is the lead sponsor of 23 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Signed .
  2. Caucasian males having confirmed diabetes mellitus type 1 (WHO criteria) for at least 12 months prior to screening.
  3. Age of 18-65 (both incl.).
  4. HbA1С ≤ 8,0 %.
  5. Insulin therapy in stable doses at least 3 months. Total dose of insulin ≤ 1,2 IU/kg per day.
  6. At least 6 months of Lantus use.
  7. C-peptide ≤ 0,3 nM/L (or 0,5 ng/mL).
  8. equal to 18.5-32.0 kg/m2.
  9. Subject must use, with their partner, methods of highly effective throughout the study.
  10. Subject is able and willing to comply with the requirements of the study protocol.

Exclusion criteria

Exclusion Criteria:

  1. Acute inflammatory diseases within 3 weeks before the screening period.
  2. History or presence of uncontrolled diabetes mellitus for 6 months prior to screening.
  3. diabetes mellitus complications (proliferative retinopathy, severe diabetic neuropathy, diabetic nephropathy ( \< 60 mL/min/1,73 m2), diabetic foot).
  4. Clinically significant deviations in basic vital signs (blood pressure, heart rate, respiration rate, body temperature), and lab tests.
  5. Deep vein thrombosis of lower extremities in a history of life or in a family history.
  6. Taking medications (excl. insulin and ACE-inhibitors), phytopreparations, biologically active supplements less than 14 days before screening.
  7. Donor blood donation or another blood loss, less than 3 months before the study.
  8. Recovery after surgery process.
  9. Mental, physical and other reasons that do not allow to adequately assess their behavior and properly fulfill the conditions of the research protocol, including psychiatric disorders.
  10. History of significant drugs abuse conditions for 3 years prior to screening.
  11. Positive testing for drugs.
  12. Receiving more than 10 units. alcohol per week (1 unit of alcohol is equivalent to 0.5 liters of beer, 200 ml of wine or 50 ml of strong alcohol) or anamnestic information about alcoholism.
  13. Positive testing for alcohol.
  14. Nicotine dependence (use of tobacco less than 6 months before the start of screening).
  15. Positive test results for or , , syphilis.
  16. Presence of suspicions of an inflammatory disease of the urinary system as a result of urinalysis.
  17. Weighed allergic anamnesis.
  18. Presence of oncology disease in the anamnesis 5 years prior the start of screening.
  19. Organ transplantation in anamnesis (excl. cornea transplantation at least 3 month prior the IP administration).
  20. Participation in a clinical trial of any medications less than 3 months before the IP administration.
  21. Any other conditions that make it difficult, according to the informed opinion of the investigating physician, that volunteer participation in studies.
  22. History of to insulin, heparin and of the drugs using in study.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
42 participants (actual)

Study arms

  • Experimental
    RinGlar®

    Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg

    Drug: RinGlar®

  • Active comparator
    Lantus®

    Single subcutaneous administration of Lantus® in dose 0.6 Units/kg

    Drug: Lantus®

Interventions

  • Single subcutaneous administration of RinGlar® in dose 0.6 Units/kg

    Also known as: insulin glargine

  • Single subcutaneous administration of Lantus® in dose 0.6 Units/kg

    Also known as: insulin glargine

06

What researchers measure

Primary outcomes

  1. AUC GIR(0-t)

    Pharmacodynamic of insulin glargine by Assessment of GIR Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))

    Time frame: 0 hours (pre-dose), as well as at, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900, 960, 1020, 1080, 1140, 1200, 1260, 1320, 1380, 1440 minutes post-dose

  2. AUC(0-t)

    Pharmacokinetics of insulin glargine by Assessment of Area Under the Curve From Time Zero Extrapolated to "t" (AUC(0-t))

    Time frame: -60, -30 and 0 hours (pre-dose), as well as at, 30, 60, 90, 120, 150, 180, 210, 240, 270, 300, 330, 360, 420, 480, 540, 600, 660, 720, 780, 840, 900, 960, 1020, 1080, 1140, 1200, 1260, 1320, 1380, 1440 minutes post-dose

07

Study locations

2 sites
  • Endocrinology Research Centre
    Moscow, 117036, Russian Federation
  • Almazov National Medical Research Centre
    Saint Petersburg, 197341, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Feb 2018, 4 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 24, 2019
StartActual
Oct 16, 2017
Primary completionActual
Feb 16, 2018
CompletionActual
Feb 16, 2018
Last update
Sep 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04101383
Lead sponsor
Geropharm
Responsible party
Sponsor
First posted
Sep 24, 2019
Start date
Oct 16, 2017
Primary completion
Feb 16, 2018
Completion
Feb 16, 2018
Last update
Sep 24, 2019

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Glargine

Start the discussion